Compare Morgan Stanley (MS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Natera Inc. Common Stock — how do they compare? Morgan Stanley trades at $181.59 (market cap $293.13B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Morgan Stanley is far larger — about 5.1× Natera Inc. Common Stock's market cap, and Morgan Stanley pays a 2.46% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 90 Days and Natera Inc. Common Stock for 0 Days on average.
| MS | NTRA | |
|---|---|---|
Market Cap | $293.13B | $57.03B |
Volume | 8,184,975 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $228.42 | $425.64 |
52-Week Low | $154.37 | $179.42 |
Typical Hold Time | 90 Days | 0 Days |
Enterprise Value | $658.86B | $56.18B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $190.02, showing stability with no recent price change. The stock exhibits a bearish technical signal but maintains strong fundamentals, with revenue growing to $66.0B in 2025 and net income reaching $16.9B. Recent earnings have consistently beaten expectations, and analyst consensus remains bullish with a $229.25 price target. The company highlights growth in wealth management and AI financing as key drivers.
The outlook for MS is positive, supported by earnings momentum and strategic growth areas, though risks include volatile cash flows and high debt levels. Investment opportunity lies in its above-sector profitability and analyst upside, but investors should monitor macroeconomic sensitivity and competitive pressures in financial services.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
